Company intelligence / Profile preview
IDAC Theranostics
Tokyo, Tokyo, Japan
- Ownership
- Private
- Development stage
- Other
01
Overview
IDAC Theranostics is conducting a Phase 1 clinical trial of IT1208, a humanized anti-CD4 monoclonal antibody for the treatment of solid tumors, with preclinical data supporting immunomodulatory antitumor activity through depletion of CD4+ T cells; additional research is directed toward HIV eradication.[4]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Kyowa Hakko Kirin (licensor of anti-CD4 antibody technology)ONO Pharmaceutical (option and evaluation/licensing agreement for IT1208)
Beyond the preview
Go deeper on IDAC Theranostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDAC Theranostics.